Cryo-Cell International Inc (CCEL) stock
CCELNYSEServices-Misc Health & Allied Services, NECFiscal year ends November 30
$4.55−0.30 (-6.19%)
Close on Nov 16, 2026Market cap $36.69MP/E –Yield –
Cryo-Cell International operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cryo-Cell International's operating income for the twelve months ending Aug 31, 2026 was $189.42K, down 95.6% year over year. For fiscal 2025 it was $482.39K, down 86.1% from the year before. Over ten years it grew -16.5% a year on average. The highest annual figure on record is $7.66M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $482.39K | -86.1% |
| FY2024 | Nov 30, 2024 | $3.48M | – |
| FY2023 | Nov 30, 2023 | -$12.30M | -405.7% |
| FY2022 | Nov 30, 2022 | $4.02M | +0.2% |
| FY2021 | Nov 30, 2021 | $4.02M | -47.6% |
| FY2020 | Nov 30, 2020 | $7.66M | +51.3% |
| FY2019 | Nov 30, 2019 | $5.06M | -2.4% |
| FY2018 | Nov 30, 2018 | $5.19M | +3.7% |
| FY2017 | Nov 30, 2017 | $5.01M | +1054.6% |
| FY2016 | Nov 30, 2016 | $433.59K | -85.2% |
| FY2015 | Nov 30, 2015 | $2.93M | +48.1% |
| FY2014 | Nov 30, 2014 | $1.98M | +16.4% |
| FY2013 | Nov 30, 2013 | $1.70M | – |
| FY2012 | Nov 30, 2012 | -$1.71M | – |
| FY2011 | Nov 30, 2011 | -$276.74K | -108.3% |
| FY2010 | Nov 30, 2010 | $3.35M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $2.19M | +15.4% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $1.20M | -19.8% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $765.13K | -27.5% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$3.97M | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $1.90M | +36.7% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $1.49M | +7.3% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $1.06M | +28.6% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$122.35K | – |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $1.39M | +19.7% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $1.39M | +35.4% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $821.22K | -51.2% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -$16.18M | -4090.6% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $1.16M | +21.7% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $1.03M | -13.9% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $1.68M | +14.5% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $405.36K | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $954.31K | -40.2% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $1.19M | -40.1% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $1.47M | +19.0% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$808.43K | -137.1% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $1.60M | -35.6% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $2.00M | +13.9% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $1.24M | -1.1% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $2.18M | +26.8% |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $2.48M | +24.4% |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $1.75M | +252.9% |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $1.25M | +46.3% |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $1.72M | -19.4% |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | $1.99M | +116.6% |
| Q2 FY2019CQ2 2019 | May 31, 2019 | $496.56K | -56.8% |
| Q1 FY2019CQ1 2019 | Feb 28, 2019 | $853.66K | -13.5% |
| Q4 FY2018CQ4 2018 | Nov 30, 2018 | $2.13M | +71.2% |
| Q3 FY2018CQ3 2018 | Aug 31, 2018 | $920.12K | -36.6% |
| Q2 FY2018CQ2 2018 | May 31, 2018 | $1.15M | -3.6% |
| Q1 FY2018CQ1 2018 | Feb 28, 2018 | $987.14K | -11.6% |
| Q4 FY2017CQ4 2017 | Nov 30, 2017 | $1.25M | +172.6% |
| Q3 FY2017CQ3 2017 | Aug 31, 2017 | $1.45M | – |
| Q2 FY2017CQ2 2017 | May 31, 2017 | $1.19M | – |
| Q1 FY2017CQ1 2017 | Feb 28, 2017 | $1.12M | – |
| Q4 FY2016CQ4 2016 | Nov 30, 2016 | $456.86K | – |
See a number that looks wrong?